Brain and genomic DNA

Featured image by Yuichiro Chino/Getty Images

Biotech

Foresite Capital’s $900M VC fund bets on AI to aid biotech plays

Foresite’s latest fund follows a 2023 comeback for early-stage biopharma startups, with median pre-money valuations soaring 33% year-over-year.

In one illustration of a continued drumbeat of interest in venture capital biotech plays, Foresite Capital has locked down $900 million for its latest vehicle.

Foresite Capital Fund VI marks the largest single-fund raise for the California-based firm. It comes as top biotech startups have shaken off high interest rates to maintain attractive valuations—with eyes on a crop of promising IPOs on the 2024 docket.

Emerging biotech AI applications, as well as broader venture healthcare bets, are poised to play a key role in Foresite’s strategy, which includes early-stage and acceleration capital, two executives told PitchBook News. Foresite and Arch Venture Partners incubated San Francisco-based AI drug discovery startup Xaira Therapeutics, which launched with more than $1 billion in funding in April.

Vik Bajaj, the chief executive of Foresite’s affiliate incubator, Foresite Labs, said the crux of the approach is to build “machine learning models that actually achieve a foundational understanding of biology.”

Vik Bajaj Foresite Capital.jpg

Bajaj

Courtesy of Foresite Capital

The challenge: Consumer-facing machine learning models built on data-hungry large language models, such as OpenAI‘s ChatGPT, have the internet at their disposal—plus books and millions of hours of video and audio covering every topic imaginable.

But the early innings of AI drug discovery hinge upon original, biological data collection that mass-market LLMs are not equipped to handle, let alone draw their conclusions from. Use cases for LLMs, according to Bajaj, are more apparent once clinical trials come into play.

“You’re going to see [AI companies] in partnerships with pharmaceutical companies and other entities—their goal is to transform those intermediate practices where the task involves laborious, rote examination of human data,” Bajaj said.

Biotech bounties

Prices for biopharma companies have continued to rise despite lower overall VC investment. The median pre-money valuation for early-stage biopharma startups neared $60 million last year, a 33% jump from 2022, according to PitchBook data.

Foresite is watching the evolving whims of limited partners, according to managing director Hadi Tabbaa, who oversees fundraising. The firm’s previous flagship fund closed on $775 million in 2021.

“In this market, largely due to interest rates—and what that’s done to peoples’ risk appetites—[there has been a] move away from backing [growth-oriented, cash-burning] platform technology companies to the same degree as three years ago,” Tabbaa said. “Now, where you see the majority of value accruing, certainly in the small- to mid-cap space in biotech … is to companies which have a path to commercialization and, therefore, M&A.”

Bajaj, who also serves as director and interim president of Xaira, said AI-driven and precision medicine technologies, including DNA sequencing, may soon make it “possible to reach targets that you cannot reach with any other techniques. … It’s a route to open up so-called ‘undruggable biology.’”

Xaira’s billion-dollar raise was one of the largest VC rounds for a biopharma company on record. Foresite and Arch led the round at an undisclosed valuation.

Xaira is Foresite’s latest big bet. It joins Alumis, a company focused on treating immune system deficiencies, which raised a $259 million Series C co-led by the firm in March. Last year, Foresite co-led a $105 million round for CG Oncology, which went public in January.

Foresite’s portfolio companies have received FDA approval for 58 drugs, according to the firm, which added that it has 47 IPOs and 28 mergers under its belt.

Featured image by Yuichiro Chino/Getty Images

Learn about our editorial standards.